BioRestorative Plays a Familiar Card to Keep Its Nasdaq Listing

MELVILLE, NY – September 02, 2026

BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced a 1-for-20 reverse stock split, a decisive financial maneuver designed to rescue its stock price from sub-dollar territory and preserve its coveted spot on The Nasdaq Capital Market. While the move is a standard corporate tactic to regain compliance with the exchange's $1.00 minimum bid price rule, for BioRestorative, it's a familiar play in a long-running game of survival. The split, effective September 7, comes as the company juggles not only a languishing stock price but also a separate Nasdaq delinquency notice for a late financial filing, painting a complex picture of a company whose clinical promise is in a race against its financial realities.

A History of Financial Engineering

For investors following BioRestorative, the reverse stock split is less a surprise and more a recurring chapter. This marks the fourth time in just over a decade the regenerative medicine firm has consolidated its shares to artificially inflate its price. The company executed a 1-for-50 split in 2013, a 1-for-20 split in 2015 to facilitate its original uplisting to Nasdaq, and a staggering 1-for-4,000 split in 2021. This pattern highlights a persistent challenge for the company: maintaining investor confidence and a market valuation that meets the exchange's basic requirements.

The mechanics are straightforward. Effective September 8, every twenty shares of BRTX common stock will be converted into a single share, reducing the number of outstanding shares from over 27.6 million to approximately 1.4 million. In theory, a stock trading at $0.05 would jump to $1.00, satisfying Nasdaq Rule 5550(a)(2). However, market history shows that such maneuvers are often perceived by investors as a sign of fundamental weakness.

"Reverse splits are frequently a temporary fix, not a long-term solution," noted one market analyst who covers the small-cap biotech space. "They address the symptom—a low stock price—but not the underlying cause. Without significant positive news on the clinical or financial front, the stock price often erodes back toward its previous levels."

The company has structured the split with a shareholder-friendly provision for fractional shares; holders who would end up with a fraction of a share will be rounded up to one full share. But this small concession does little to mask the larger concern that the split is a defensive move born of necessity rather than a strategic step from a position of strength.

The Numbers Behind the Necessity

A look at BioRestorative's financial health reveals why such drastic measures are necessary. The company is a classic example of a pre-revenue clinical-stage biotech: its value lies in future potential, but its present is defined by significant cash burn. In the last twelve months, the company reported a net loss of over $11 million on just $357,870 in revenue. Its operating cash flow was a negative $11.82 million over the same period.

With only $3.59 million in cash on its books as of its last report, this burn rate creates a short runway to fund its ambitious research and development programs. Financial health indicators paint a grim picture: a deeply negative Altman Z-Score of -57.29 suggests a heightened risk of bankruptcy, while its Return on Equity stands at a staggering -241%.

Compounding these financial pressures is a recent regulatory headache. On August 21, BioRestorative received a delinquency notice from Nasdaq for failing to file its quarterly 10-Q report on time. The company now has until October 20 to submit a compliance plan. While extensions are possible, the failure to meet basic reporting deadlines adds a layer of "governance uncertainty," as one AI-driven analyst report from TipRanks described it. This dual compliance battle—one over its stock price and another over its financial reporting—puts immense pressure on the company's new leadership, which was only recently announced on September 1.

The reverse split also serves another critical purpose: it makes the company's stock more attractive for potential future financing rounds. A sub-dollar stock is often unappealing to institutional investors and can complicate capital raises. By lifting the price, BioRestorative may find it easier to secure the funds needed to continue its operations, though this often comes at the cost of future dilution for existing shareholders.

Can Promising Science Outrun a Ticking Clock?

Lost amid the financial restructuring is the science that forms the core of BioRestorative's potential value. The company's lead candidate, BRTX-100, is a cell-based therapy targeting chronic lumbar disc disease, a condition affecting millions and representing a massive market opportunity. Formulated from a patient's own stem cells, BRTX-100 is currently in a Phase 2 clinical trial. In a positive development, the company announced in June that it had completed the manufacturing for this crucial trial, a key operational milestone.

Its second program, ThermoStem®, is focused on using brown fat stem cells to develop treatments for metabolic disorders like Type 2 Diabetes and obesity. While still in earlier, preclinical stages, this program targets another area of significant unmet medical need. The firm has also attempted to generate near-term revenue through a commercial biocosmeceutical platform, recently appointing a new Vice President to accelerate its expansion. However, a recent halt in sales of its ExoCR and BioX products for regulatory review could hamper this effort.

This is the central tension for BioRestorative and its investors. The company possesses promising assets in high-value therapeutic areas. But translating that promise from prototype to profit requires immense capital and time. The constant need for financial maneuvers like reverse splits can distract from and even threaten the progress of these clinical programs. The question is whether the company can keep the lights on long enough to get BRTX-100 through its Phase 2 trial and deliver the kind of positive data that would fundamentally change its financial trajectory.

A Symptom of a Broader Biotech Struggle

BioRestorative's predicament is not unique. The landscape is littered with small-cap biotech companies that have promising science but struggle to navigate the "valley of death" between early-stage research and commercial viability. Maintaining a Nasdaq listing is paramount, as it provides the liquidity and access to capital necessary to fund multi-year, multi-million-dollar clinical trials.

For these companies, a reverse split is a tool in the survival kit, used to reset the clock on a potential delisting. However, it often puts them in a precarious position. The move can attract short-sellers who bet that the stock price will decline post-split, and it can alienate long-term retail investors who see their share counts decimated.

Ultimately, the success of BioRestorative's reverse split will not be measured on September 8 when the stock begins trading at its new, higher price. It will be measured in the months that follow. The market will be watching to see if the company can resolve its 10-Q filing delinquency, secure non-dilutive funding, and, most importantly, deliver positive clinical data from its BRTX-100 trial. Without these fundamental catalysts, this 1-for-20 split risks becoming just another temporary patch on a company struggling to turn its scientific vision into a commercially viable reality.